Aim: Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. Materials & methods: In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Results: Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). Conclusion: PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.
|Number of pages||12|
|Publication status||Published - 2022 Jul|
Bibliographical noteFunding Information:
SY Rha has served as a consultant and speaker for Eli Lilly and as a consultant for Merck Sharp & Dohme (MSD), Celltrion, and Ipsen and has received research funding from Bristol-Myers Squibb (BMS) and MSD. GY Ku: is a consultant for and has received research funding from Merck & Co., Inc., AstraZeneca, BMS and Pieris; has served as a consultant for Eli Lilly; and has received research funding from Arog Pharma and Aduro Biotech. HC Chung has received honoraria, is a consultant for, and has received research funding from Merck Serono and Eli Lilly; has received honoraria from Foundation Medicine; is a consultant for Taiho, Celltrion, Quintiles, BMS and MSD; and has received research funding from GlaxoSmithKline, BMS-Ono Pharmaceuticals, MSD and Taiho. W Zhou, T Wu and SA Peter are current or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA; W Zhou and SA Peter own stock in Merck & Co., Inc., NJ, USA. JA Ajani has received research funding from BMS, Merck & Co. Inc., Astellas, Taiho, DeltaFly, Prolinx, Macrogenics, and Zymeworks and honoraria from BMS, Merck & Co. Inc., Astellas, Taiho, Zymeworks, DAVA/OM, AstraZeneca, Acrotech, and Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing and/or editorial assistance was provided by T Stuve and J Burke of the ApotheCom pembrolizumab team (PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA.
© 2022 Future Medicine Ltd.
All Science Journal Classification (ASJC) codes
- Cancer Research